ID   BTK_HUMAN               Reviewed;         659 AA.
AC   Q06187; B2RAW1; Q32ML5;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   12-OCT-2022, entry version 258.
DE   RecName: Full=Tyrosine-protein kinase BTK;
DE            EC=2.7.10.2;
DE   AltName: Full=Agammaglobulinemia tyrosine kinase;
DE            Short=ATK;
DE   AltName: Full=B-cell progenitor kinase;
DE            Short=BPK;
DE   AltName: Full=Bruton tyrosine kinase;
GN   Name=BTK; Synonyms=AGMX1, ATK, BPK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BTK-A).
RX   PubMed=8380905; DOI=10.1038/361226a0;
RA   Vetrie D., Vorechovsky I., Sideras P., Holland J., Davies A., Flinter F.,
RA   Hammarstroem L., Kinnon C., Levinsky R.J., Bobrow M., Smith C.I.E.,
RA   Bentley D.R.;
RT   "The gene involved in X-linked agammaglobulinaemia is a member of the src
RT   family of protein-tyrosine kinases.";
RL   Nature 361:226-233(1993).
RN   [2]
RP   ERRATUM OF PUBMED:8380905.
RA   Vetrie D., Vorechovsky I., Sideras P., Holland J., Davies A., Flinter F.,
RA   Hammarstroem L., Kinnon C., Levinsky R.J., Bobrow M., Smith C.I.E.,
RA   Bentley D.R.;
RL   Nature 364:362-362(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=8090769; DOI=10.1073/pnas.91.19.9062;
RA   Ohta Y., Haire R.N., Litman R.T., Fu S.M., Nelson R.P., Kratz J.,
RA   Kornfeld S.J., la Morena M., Good R.A., Litman G.W.;
RT   "Genomic organization and structure of Bruton agammaglobulinemia tyrosine
RT   kinase: localization of mutations associated with varied clinical
RT   presentations and course in X chromosome-linked agammaglobulinemia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:9062-9066(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7927535; DOI=10.1007/bf01246672;
RA   Rohrer J., Parolini O., Belmont J.W., Conley M.E.;
RT   "The genomic structure of human BTK, the defective gene in X-linked
RT   agammaglobulinemia.";
RL   Immunogenetics 40:319-324(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS XLA SER-334; ARG-506;
RP   GLN-520; TRP-562 AND LYS-630.
RX   PubMed=7880320; DOI=10.1093/hmg/3.10.1743;
RA   Hagemann T.L., Chen Y., Rosen F.S., Kwan S.-P.;
RT   "Genomic organization of the Btk gene and exon scanning for mutations in
RT   patients with X-linked agammaglobulinemia.";
RL   Hum. Mol. Genet. 3:1743-1749(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7626884; DOI=10.1007/bf00364796;
RA   Oeltjen J.C., Liu X., Lu J., Allen R.C., Muzny D.M., Belmont J.W.,
RA   Gibbs R.A.;
RT   "Sixty-nine kilobases of contiguous human genomic sequence containing the
RT   alpha-galactosidase A and Bruton's tyrosine kinase loci.";
RL   Mamm. Genome 6:334-338(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BTK-A).
RC   TISSUE=Umbilical cord blood;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BTK-A).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE OF 1-442.
RX   PubMed=8425221; DOI=10.1016/0092-8674(93)90667-f;
RA   Tsukada S., Saffran D.C., Rawlings D.J., Parolini O., Allen R.C.,
RA   Klisak I., Sparkes R.S., Kubagawa H., Mohandas T., Quan S., Belmont J.W.,
RA   Cooper M.D., Conley M.E., Witte O.N.;
RT   "Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-
RT   linked agammaglobulinemia.";
RL   Cell 72:279-290(1993).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-12 AND 323-332, CLEAVAGE OF INITIATOR METHIONINE,
RP   ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Platelet;
RA   Bienvenut W.V., Claeys D.;
RL   Submitted (NOV-2005) to UniProtKB.
RN   [12]
RP   PROTEIN SEQUENCE OF 219-235, AND PHOSPHORYLATION AT TYR-223.
RX   PubMed=12573241; DOI=10.1016/s1570-9639(02)00524-1;
RA   Nore B.F., Mattsson P.T., Antonsson P., Backesjo C.-M., Westlund A.,
RA   Lennartsson J., Hansson H., Low P., Ronnstrand L., Smith C.I.E.;
RT   "Identification of phosphorylation sites within the SH3 domains of Tec
RT   family tyrosine kinases.";
RL   Biochim. Biophys. Acta 1645:123-132(2003).
RN   [13]
RP   INVOLVEMENT IN IGHD3.
RX   PubMed=8013627; DOI=10.1016/0014-5793(94)00457-9;
RA   Duriez B., Duquesnoy P., Dastot F., Bougneres P., Amselem S., Goossens M.;
RT   "An exon-skipping mutation in the btk gene of a patient with X-linked
RT   agammaglobulinemia and isolated growth hormone deficiency.";
RL   FEBS Lett. 346:165-170(1994).
RN   [14]
RP   DOMAIN PH.
RX   PubMed=8070576; DOI=10.1016/0014-5793(94)00783-7;
RA   Vihinen M., Nilsson L., Smith C.I.;
RT   "Tec homology (TH) adjacent to the PH domain.";
RL   FEBS Lett. 350:263-265(1994).
RN   [15]
RP   PHOSPHORYLATION AT TYR-223 AND TYR-551, MUTAGENESIS OF TYR-223, AND
RP   ACTIVITY REGULATION.
RX   PubMed=8630736; DOI=10.1016/s1074-7613(00)80417-3;
RA   Park H., Wahl M.I., Afar D.E., Turck C.W., Rawlings D.J., Tam C.,
RA   Scharenberg A.M., Kinet J.P., Witte O.N.;
RT   "Regulation of Btk function by a major autophosphorylation site within the
RT   SH3 domain.";
RL   Immunity 4:515-525(1996).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF GTF2I, PHOSPHORYLATION AT TYR-223 AND
RP   TYR-551, AND MUTAGENESIS OF GLU-41; PRO-189; TYR-223; TRP-251; ARG-307 AND
RP   TYR-551.
RX   PubMed=9012831; DOI=10.1073/pnas.94.2.604;
RA   Yang W., Desiderio S.;
RT   "BAP-135, a target for Bruton's tyrosine kinase in response to B cell
RT   receptor engagement.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:604-609(1997).
RN   [17]
RP   MUTAGENESIS OF 251-TRP-TRP-252, AND INTERACTION WITH SH3BP5.
RX   PubMed=9571151; DOI=10.1006/bbrc.1998.8420;
RA   Matsushita M., Yamadori T., Kato S., Takemoto Y., Inazawa J., Baba Y.,
RA   Hashimoto S., Sekine S., Arai S., Kunikata T., Kurimoto M., Kishimoto T.,
RA   Tsukada S.;
RT   "Identification and characterization of a novel SH3-domain binding protein,
RT   Sab, which preferentially associates with Bruton's tyrosine kinase (Btk).";
RL   Biochem. Biophys. Res. Commun. 245:337-343(1998).
RN   [18]
RP   DOMAIN PH, AND SUBCELLULAR LOCATION.
RX   PubMed=10196179; DOI=10.1074/jbc.274.16.10983;
RA   Varnai P., Rother K.I., Balla T.;
RT   "Phosphatidylinositol 3-kinase-dependent membrane association of the
RT   Bruton's tyrosine kinase pleckstrin homology domain visualized in single
RT   living cells.";
RL   J. Biol. Chem. 274:10983-10989(1999).
RN   [19]
RP   INTERACTION WITH SH3BP5, AND ACTIVITY REGULATION.
RX   PubMed=10339589; DOI=10.1073/pnas.96.11.6341;
RA   Yamadori T., Baba Y., Mastushita M., Hashimoto S., Kurosaki M.,
RA   Kurosaki T., Kishimoto T., Tsukada S.;
RT   "Bruton's tyrosine kinase activity is negatively regulated by Sab, the Btk-
RT   SH3 domain-binding protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:6341-6346(1999).
RN   [20]
RP   SUBCELLULAR LOCATION.
RX   PubMed=10602036;
RX   DOI=10.1002/1521-4141(200001)30:1<145::aid-immu145>3.0.co;2-0;
RA   Nore B.F., Vargas L., Mohamed A.J., Branden L.J., Backesjo C.M.,
RA   Islam T.C., Mattsson P.T., Hultenby K., Christensson B., Smith C.I.;
RT   "Redistribution of Bruton's tyrosine kinase by activation of
RT   phosphatidylinositol 3-kinase and Rho-family GTPases.";
RL   Eur. J. Immunol. 30:145-154(2000).
RN   [21]
RP   SUBCELLULAR LOCATION.
RX   PubMed=11016936; DOI=10.1074/jbc.m006952200;
RA   Mohamed A.J., Vargas L., Nore B.F., Backesjo C.M., Christensson B.,
RA   Smith C.I.;
RT   "Nucleocytoplasmic shuttling of Bruton's tyrosine kinase.";
RL   J. Biol. Chem. 275:40614-40619(2000).
RN   [22]
RP   PHOSPHORYLATION AT SER-180, AND ACTIVITY REGULATION.
RX   PubMed=11598012; DOI=10.1093/emboj/20.20.5692;
RA   Kang S.W., Wahl M.I., Chu J., Kitaura J., Kawakami Y., Kato R.M.,
RA   Tabuchi R., Tarakhovsky A., Kawakami T., Turck C.W., Witte O.N.,
RA   Rawlings D.J.;
RT   "PKCbeta modulates antigen receptor signaling via regulation of Btk
RT   membrane localization.";
RL   EMBO J. 20:5692-5702(2001).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF PLCG2.
RX   PubMed=11606584; DOI=10.1074/jbc.m107577200;
RA   Rodriguez R., Matsuda M., Perisic O., Bravo J., Paul A., Jones N.P.,
RA   Light Y., Swann K., Williams R.L., Katan M.;
RT   "Tyrosine residues in phospholipase Cgamma 2 essential for the enzyme
RT   function in B-cell signaling.";
RL   J. Biol. Chem. 276:47982-47992(2001).
RN   [24]
RP   INTERACTION WITH IBTK, AND ACTIVITY REGULATION.
RX   PubMed=11577348; DOI=10.1038/ni1001-939;
RA   Liu W., Quinto I., Chen X., Palmieri C., Rabin R.L., Schwartz O.M.,
RA   Nelson D.L., Scala G.;
RT   "Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding
RT   protein.";
RL   Nat. Immunol. 2:939-946(2001).
RN   [25]
RP   DOMAIN, INTERACTION WITH CAV1, SUBCELLULAR LOCATION, AND ACTIVITY
RP   REGULATION.
RX   PubMed=11751885; DOI=10.1074/jbc.m108537200;
RA   Vargas L., Nore B.F., Berglof A., Heinonen J.E., Mattsson P.T., Smith C.I.,
RA   Mohamed A.J.;
RT   "Functional interaction of caveolin-1 with Bruton's tyrosine kinase and
RT   Bmx.";
RL   J. Biol. Chem. 277:9351-9357(2002).
RN   [26]
RP   PHOSPHORYLATION AT TYR-617 AND SER-623, AND MUTAGENESIS OF TYR-617.
RX   PubMed=15375214; DOI=10.1073/pnas.0405878101;
RA   Guo S., Ferl G.Z., Deora R., Riedinger M., Yin S., Kerwin J.L., Loo J.A.,
RA   Witte O.N.;
RT   "A phosphorylation site in Bruton's tyrosine kinase selectively regulates B
RT   cell calcium signaling efficiency by altering phospholipase C-gamma
RT   activation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:14180-14185(2004).
RN   [27]
RP   INTERACTION WITH PIN1, PHOSPHORYLATION AT SER-21 AND SER-115, AND ACTIVITY
RP   REGULATION.
RX   PubMed=16644721; DOI=10.1074/jbc.m603090200;
RA   Yu L., Mohamed A.J., Vargas L., Berglof A., Finn G., Lu K.P., Smith C.I.;
RT   "Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase
RT   Pin1.";
RL   J. Biol. Chem. 281:18201-18207(2006).
RN   [28]
RP   FUNCTION IN THE TLR PATHWAY.
RX   PubMed=16517732; DOI=10.4049/jimmunol.176.6.3635;
RA   Horwood N.J., Page T.H., McDaid J.P., Palmer C.D., Campbell J., Mahon T.,
RA   Brennan F.M., Webster D., Foxwell B.M.;
RT   "Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but
RT   not IL-6, production.";
RL   J. Immunol. 176:3635-3641(2006).
RN   [29]
RP   INTERACTION WITH GTF2I AND ARID3A, AND FUNCTION.
RX   PubMed=16738337; DOI=10.1128/mcb.02009-05;
RA   Rajaiya J., Nixon J.C., Ayers N., Desgranges Z.P., Roy A.L., Webb C.F.;
RT   "Induction of immunoglobulin heavy-chain transcription through the
RT   transcription factor Bright requires TFII-I.";
RL   Mol. Cell. Biol. 26:4758-4768(2006).
RN   [30]
RP   FUNCTION IN PHOSPHORYLATION OF TIRAP, AND ACTIVITY REGULATION.
RX   PubMed=16415872; DOI=10.1038/ni1299;
RA   Mansell A., Smith R., Doyle S.L., Gray P., Fenner J.E., Crack P.J.,
RA   Nicholson S.E., Hilton D.J., O'Neill L.A., Hertzog P.J.;
RT   "Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor
RT   signaling by mediating Mal degradation.";
RL   Nat. Immunol. 7:148-155(2006).
RN   [31]
RP   FUNCTION, INTERACTION WITH TLR8 AND TLR9, ACTIVITY REGULATION, AND
RP   PHOSPHORYLATION AT TYR-223.
RX   PubMed=17932028; DOI=10.1074/jbc.m707682200;
RA   Doyle S.L., Jefferies C.A., Feighery C., O'Neill L.A.;
RT   "Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine
RT   kinase.";
RL   J. Biol. Chem. 282:36953-36960(2007).
RN   [32]
RP   INTERACTION WITH FASLG.
RX   PubMed=19807924; DOI=10.1186/1471-2172-10-53;
RA   Voss M., Lettau M., Janssen O.;
RT   "Identification of SH3 domain interaction partners of human FasL (CD178) by
RT   phage display screening.";
RL   BMC Immunol. 10:53-53(2009).
RN   [33]
RP   REVIEW ON FUNCTION IN REGULATION OF APOPTOSIS.
RX   PubMed=9751072; DOI=10.1016/s0006-2952(98)00122-1;
RA   Uckun F.M.;
RT   "Bruton's tyrosine kinase (BTK) as a dual-function regulator of
RT   apoptosis.";
RL   Biochem. Pharmacol. 56:683-691(1998).
RN   [34]
RP   REVIEW ON FUNCTION, AND REVIEW ON ACTIVITY REGULATION.
RX   PubMed=19290921; DOI=10.1111/j.1600-065x.2008.00741.x;
RA   Mohamed A.J., Yu L., Backesjo C.M., Vargas L., Faryal R., Aints A.,
RA   Christensson B., Berglof A., Vihinen M., Nore B.F., Smith C.I.;
RT   "Bruton's tyrosine kinase (Btk): function, regulation, and transformation
RT   with special emphasis on the PH domain.";
RL   Immunol. Rev. 228:58-73(2009).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-55; THR-191; TYR-361 AND
RP   SER-659, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [36]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [37]
RP   ALTERNATIVE PROMOTER USAGE (ISOFORM BTK-C).
RX   PubMed=23913792; DOI=10.1002/gcc.22091;
RA   Eifert C., Wang X., Kokabee L., Kourtidis A., Jain R., Gerdes M.J.,
RA   Conklin D.S.;
RT   "A novel isoform of the B cell tyrosine kinase BTK protects breast cancer
RT   cells from apoptosis.";
RL   Genes Chromosomes Cancer 52:961-975(2013).
RN   [38]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-191; TYR-223 AND SER-604, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [39]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [40]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 2-170 IN COMPLEX WITH ZINC.
RX   PubMed=9218782; DOI=10.1093/emboj/16.12.3396;
RA   Hyvoenen M., Saraste M.;
RT   "Structure of the PH domain and Btk motif from Bruton's tyrosine kinase:
RT   molecular explanations for X-linked agammaglobulinaemia.";
RL   EMBO J. 16:3396-3404(1997).
RN   [41]
RP   STRUCTURE BY NMR OF 212-275.
RX   PubMed=9485443; DOI=10.1021/bi972409f;
RA   Hansson H., Mattsson P.T., Allard P., Haapaniemi P., Vihinen M.,
RA   Smith C.I.E., Haerd T.;
RT   "Solution structure of the SH3 domain from Bruton's tyrosine kinase.";
RL   Biochemistry 37:2912-2924(1998).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1-170 IN COMPLEX WITH
RP   INOSITOL-(1,3,4,5)-TETRAKISPHOSPHATE AND ZINC, AND DOMAIN PH.
RX   PubMed=10196129; DOI=10.1016/s0969-2126(99)80057-4;
RA   Baraldi E., Carugo K.D., Hyvoenen M., Surdo P.L., Riley A.M.,
RA   Potter B.V.L., O'Brien R., Ladbury J.E., Saraste M.;
RT   "Structure of the PH domain from Bruton's tyrosine kinase in complex with
RT   inositol 1,3,4,5-tetrakisphosphate.";
RL   Structure 7:449-460(1999).
RN   [43]
RP   STRUCTURE BY NMR OF 216-273.
RX   PubMed=10826882; DOI=10.1023/a:1008376624863;
RA   Tzeng S.R., Lou Y.C., Pai M.T., Jain M.L., Cheng J.W.;
RT   "Solution structure of the human BTK SH3 domain complexed with a proline-
RT   rich peptide from p120cbl.";
RL   J. Biomol. NMR 16:303-312(2000).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 397-659.
RX   PubMed=11527964; DOI=10.1074/jbc.m104828200;
RA   Mao C., Zhou M., Uckun F.M.;
RT   "Crystal structure of Bruton's tyrosine kinase domain suggests a novel
RT   pathway for activation and provides insights into the molecular basis of X-
RT   linked agammaglobulinemia.";
RL   J. Biol. Chem. 276:41435-41443(2001).
RN   [45]
RP   STRUCTURE BY NMR OF 270-386.
RX   PubMed=16969585; DOI=10.1007/s10858-006-9064-3;
RA   Huang K.C., Cheng H.T., Pai M.T., Tzeng S.R., Cheng J.W.;
RT   "Solution structure and phosphopeptide binding of the SH2 domain from the
RT   human Bruton's tyrosine kinase.";
RL   J. Biomol. NMR 36:73-78(2006).
RN   [46] {ECO:0007744|PDB:3OCS, ECO:0007744|PDB:3OCT}
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 393-656 IN COMPLEX WITH
RP   INHIBITOR.
RA   Di Paolo J.A., Huang T., Balazs M., Barbosa J., Barck K.H., Carano R.A.D.,
RA   Darrow J., Davies D.R., DeForge L.E., Dennis G. Jr., Diehl L., Ferrando R.;
RT   "A novel, specific Btk inhibitor antagonizes BCR and Fc[gamma]R signaling
RT   and suppresses inflammatory arthritis.";
RL   Submitted (AUG-2010) to the PDB data bank.
RN   [47] {ECO:0007744|PDB:2Z0P}
RP   X-RAY CRYSTALLOGRAPHY (2.58 ANGSTROMS) OF 2-170 IN COMPLEX WITH INHIBITOR
RP   AND ZINC.
RA   Murayama K., Kato-Murayama M., Mishima C., Shirouzu M., Yokoyama S.;
RT   "Crystal structure of PH domain of Bruton's tyrosine kinase.";
RL   Submitted (MAY-2007) to the PDB data bank.
RN   [48] {ECO:0007744|PDB:3GEN, ECO:0007744|PDB:3K54}
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 382-659 IN COMPLEX WITH INHIBITOR
RP   DASATINIB.
RX   PubMed=20052711; DOI=10.1002/pro.321;
RA   Marcotte D.J., Liu Y.T., Arduini R.M., Hession C.A., Miatkowski K.,
RA   Wildes C.P., Cullen P.F., Hong V., Hopkins B.T., Mertsching E.,
RA   Jenkins T.J., Romanowski M.J., Baker D.P., Silvian L.F.;
RT   "Structures of human Bruton's tyrosine kinase in active and inactive
RT   conformations suggest a mechanism of activation for TEC family kinases.";
RL   Protein Sci. 19:429-439(2010).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 393-659.
RA   Di Paolo J., Huang T., Balazs M., Barbosa J., Barck K.H., Bravo B.,
RA   Carano R.A.D., Darrow J., Davies D.R., DeForge L.E., Diehl L., Ferrando R.,
RA   Gallion S.L., Gianetti A.M., Gribling P., Hurez V., Hymowitz S.G.,
RA   Jones R., Kropf J.E., Lee W.P., Maciejewski P.M., Mitchell S.A., Rong H.,
RA   Staker B.L., Whitney J.A., Yeh S., Young W., Yu C., Zhang J., Reif K.,
RA   Currie K.S.;
RT   "A novel, specific BTK inhibitor antagonizes BCR and FcgR signaling and
RT   suppresses inflammatory arthritis.";
RL   Submitted (SEP-2010) to the PDB data bank.
RN   [50] {ECO:0007744|PDB:3PIX, ECO:0007744|PDB:3PIY, ECO:0007744|PDB:3PIZ, ECO:0007744|PDB:3PJ1, ECO:0007744|PDB:3PJ2, ECO:0007744|PDB:3PJ3}
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 387-659 IN COMPLEX WITH
RP   INHIBITOR.
RX   PubMed=21280133; DOI=10.1002/pro.575;
RA   Kuglstatter A., Wong A., Tsing S., Lee S.W., Lou Y., Villasenor A.G.,
RA   Bradshaw J.M., Shaw D., Barnett J.W., Browner M.F.;
RT   "Insights into the conformational flexibility of Bruton's tyrosine kinase
RT   from multiple ligand complex structures.";
RL   Protein Sci. 20:428-436(2011).
RN   [51]
RP   REVIEW ON VARIANTS XLA.
RX   PubMed=8594569; DOI=10.1093/nar/24.1.160;
RA   Vihinen M., Iwata T., Kinnon C., Kwan S.-P., Ochs H.D., Vorechovsky I.,
RA   Smith C.I.E.;
RT   "BTKbase, mutation database for X-linked agammaglobulinemia (XLA).";
RL   Nucleic Acids Res. 24:160-165(1996).
RN   [52]
RP   REVIEW ON VARIANTS XLA.
RX   PubMed=9016530; DOI=10.1093/nar/25.1.166;
RA   Vihinen M., Belohradsky B.H., Haire R.N., Holinski-Feder E., Kwan S.-P.,
RA   Lappalainen I., Lehvaeslaiho H., Lester T., Meindl A., Ochs H.D.,
RA   Ollila J., Vorechovsky I., Weiss M., Smith C.I.E.;
RT   "BTKbase, mutation database for X-linked agammaglobulinemia (XLA).";
RL   Nucleic Acids Res. 25:166-171(1997).
RN   [53]
RP   VARIANTS XLA TRP-288; GLY-307; ASP-607 AND SER-VAL-PHE-SER-SER-THR-ARG-103
RP   INS.
RX   PubMed=8162056; DOI=10.1093/hmg/3.1.79;
RA   Bradley L.A.D., Sweatman A.K., Lovering R.C., Jones A.M., Morgan G.,
RA   Levinsky R.J., Kinnon C.;
RT   "Mutation detection in the X-linked agammaglobulinemia gene, BTK, using
RT   single strand conformation polymorphism analysis.";
RL   Hum. Mol. Genet. 3:79-83(1994).
RN   [54]
RP   VARIANTS XLA HIS-28 AND TRP-288.
RX   PubMed=8162018; DOI=10.1093/hmg/3.1.161;
RA   de Weers M., Mensink R.G.J., Kraakman M.E.M., Schuurman R.K.B.,
RA   Hendriks R.W.;
RT   "Mutation analysis of the Bruton's tyrosine kinase gene in X-linked
RT   agammaglobulinemia: identification of a mutation which affects the same
RT   codon as is altered in immunodeficient xid mice.";
RL   Hum. Mol. Genet. 3:161-166(1994).
RN   [55]
RP   VARIANTS XLA ASP-113; CYS-361; GLN-520; PRO-542; TRP-562; LYS-630 AND
RP   PRO-652.
RX   PubMed=7849697; DOI=10.1093/hmg/3.10.1751;
RA   Conley M.E., Fitch-Hilgenberg M.E., Cleveland J.L., Parolini O., Rohrer J.;
RT   "Screening of genomic DNA to identify mutations in the gene for Bruton's
RT   tyrosine kinase.";
RL   Hum. Mol. Genet. 3:1751-1756(1994).
RN   [56]
RP   VARIANTS XLA HIS-28; PRO-33; PRO-408; GLY-589; ASP-613 AND 260-GLN--GLU-280
RP   DEL.
RX   PubMed=7849721; DOI=10.1093/hmg/3.10.1899;
RA   Zhu Q., Zhang M., Winkelstein J., Chen S.-H., Ochs H.D.;
RT   "Unique mutations of Bruton's tyrosine kinase in fourteen unrelated X-
RT   linked agammaglobulinemia families.";
RL   Hum. Mol. Genet. 3:1899-1900(1994).
RN   [57]
RP   VARIANTS XLA GLU-430; GLN-520; GLN-525; PRO-562; VAL-582; GLY-589; GLU-594
RP   AND ASP-613.
RX   PubMed=7809124; DOI=10.1073/pnas.91.26.12803;
RA   Vihinen M., Vetrie D., Maniar H.S., Ochs H.D., Zhu Q., Vorechovsky I.,
RA   Webster A.D.B., Notarangelo L.D., Nilsson L., Sowadski J.M., Smith C.I.E.;
RT   "Structural basis for chromosome X-linked agammaglobulinemia: a tyrosine
RT   kinase disease.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:12803-12807(1994).
RN   [58]
RP   VARIANT XLA PHE-64, AND CHARACTERIZATION OF OTHER XLA VARIANTS.
RX   PubMed=7849006; DOI=10.1021/bi00005a002;
RA   Vihinen M., Zvelebil J.J.M., Zhu Q., Brooimans R.A., Ochs H.D.,
RA   Zegers B.J.M., Nilsson L., Waterfield M.D., Smith C.I.E.;
RT   "Structural basis for pleckstrin homology domain mutations in X-linked
RT   agammaglobulinemia.";
RL   Biochemistry 34:1475-1481(1995).
RN   [59]
RP   VARIANTS XLA SER-25; TRP-288; MET-370; VAL-509; PRO-525; LYS-526; TRP-562;
RP   VAL-582 AND ARG-594.
RX   PubMed=7711734; DOI=10.1093/hmg/4.1.51;
RA   Vorechovsky I., Vihinen M., de Saint Basile G., Honsova S.,
RA   Hammarstroem L., Mueller S., Nilsson L., Fischer A., Smith C.I.E.;
RT   "DNA-based mutation analysis of Bruton's tyrosine kinase gene in patients
RT   with X-linked agammaglobulinaemia.";
RL   Hum. Mol. Genet. 4:51-58(1995).
RN   [60]
RP   VARIANTS XLA LYS-567; LEU-587 AND HIS-641.
RX   PubMed=7633420; DOI=10.1093/hmg/4.4.693;
RA   Jin H., Webster A.D.B., Vihinen M., Sideras P., Vorechovsky I.,
RA   Hammarstroem L., Bernatowska-Matuszkiewicz E., Smith C.I.E., Bobrow M.,
RA   Vetrie D.;
RT   "Identification of Btk mutations in 20 unrelated patients with X-linked
RT   agammaglobulinaemia (XLA).";
RL   Hum. Mol. Genet. 4:693-700(1995).
RN   [61]
RP   VARIANTS XLA PRO-33; GLY-302 DEL; GLN-520 AND CYS-641.
RX   PubMed=7633429; DOI=10.1093/hmg/4.4.755;
RA   Gaspar H.B., Bradley L.A.D., Katz F., Lovering R.C., Roifman C.M.,
RA   Morgan G., Levinsky R.J., Kinnon C.;
RT   "Mutation analysis in Bruton's tyrosine kinase, the X-linked
RT   agammaglobulinaemia gene, including identification of an insertional
RT   hotspot.";
RL   Hum. Mol. Genet. 4:755-757(1995).
RN   [62]
RP   VARIANTS XLA ASN-429 AND ARG-477.
RX   PubMed=8634718; DOI=10.1093/hmg/4.12.2403;
RA   Vorechovsky I., Luo L., de Saint Basile G., Hammarstroem L.,
RA   Webster A.D.B., Smith C.I.E.;
RT   "Improved oligonucleotide primer set for molecular diagnosis of X-linked
RT   agammaglobulinaemia: predominance of amino acid substitutions in the
RT   catalytic domain of Bruton's tyrosine kinase.";
RL   Hum. Mol. Genet. 4:2403-2405(1995).
RN   [63]
RP   VARIANTS XLA GLU-302 AND ASP-476.
RX   PubMed=7627183; DOI=10.1002/humu.1380050405;
RA   Hagemann T.L., Rosen F.S., Kwan S.-P.;
RT   "Characterization of germline mutations of the gene encoding Bruton's
RT   tyrosine kinase in families with X-linked agammaglobulinemia.";
RL   Hum. Mutat. 5:296-302(1995).
RN   [64]
RP   VARIANT XLA PHE-358.
RX   PubMed=7897635; DOI=10.1136/jmg.32.1.77;
RA   Ohashi Y., Tsuchiya S., Konno T.;
RT   "A new point mutation involving a highly conserved leucine in the Btk SH2
RT   domain in a family with X linked agammaglobulinaemia.";
RL   J. Med. Genet. 32:77-79(1995).
RN   [65]
RP   VARIANT XLA PRO-295.
RX   PubMed=8723128;
RX   DOI=10.1002/(sici)1096-8628(19960503)63:1<318::aid-ajmg53>3.0.co;2-n;
RA   Schuster V., Seidenspinner S., Kreth H.W.;
RT   "Detection of a novel mutation in the SRC homology domain 2 (SH2) of
RT   Bruton's tyrosine kinase and direct female carrier evaluation in a family
RT   with X-linked agammaglobulinemia.";
RL   Am. J. Med. Genet. 63:318-322(1996).
RN   [66]
RP   VARIANTS XLA ARG-12; PRO-28; GLU-302; TRP-502; HIS-521; TYR-633 AND
RP   SER-644.
RX   PubMed=8695804;
RA   Hashimoto S., Tsukada S., Matsushita M., Miyawaki T., Niida Y., Yachie A.,
RA   Kobayashi S., Iwata T., Hayakawa H., Matsuoka H., Tsuge I., Yamadori T.,
RA   Kunikata T., Arai S., Yoshizaki K., Taniguchi N., Kishimoto T.;
RT   "Identification of Bruton's tyrosine kinase (Btk) gene mutations and
RT   characterization of the derived proteins in 35 X-linked agammaglobulinemia
RT   families: a nationwide study of Btk deficiency in Japan.";
RL   Blood 88:561-573(1996).
RN   [67]
RP   VARIANTS XLA TRP-288; LYS-544 AND PRO-592.
RX   PubMed=8834236; DOI=10.1007/bf02267060;
RA   Kobayashi S., Iwata T., Saito M., Iwasaki R., Matsumoto H., Naritaka S.,
RA   Kono Y., Hayashi Y.;
RT   "Mutations of the Btk gene in 12 unrelated families with X-linked
RT   agammaglobulinemia in Japan.";
RL   Hum. Genet. 97:424-430(1996).
RN   [68]
RP   VARIANTS XLA SER-154 AND ARG-155.
RX   PubMed=9280283; DOI=10.1016/s0014-5793(97)00912-5;
RA   Vihinen M., Nore B., Mattsson P.T., Backesj C.-M., Nars M., Koutaniemi S.,
RA   Watanabe C., Lester T., Jones A.M., Ochs H.D., Smith C.I.E.;
RT   "Missense mutations affecting a conserved cysteine pair in the TH domain of
RT   Btk.";
RL   FEBS Lett. 413:205-210(1997).
RN   [69]
RP   VARIANTS XLA.
RX   PubMed=9260159; DOI=10.1007/bf03401694;
RA   Saha B.K., Curtis S.K., Vogler L.B., Vihinen M.;
RT   "Molecular and structural characterization of five novel mutations in the
RT   Bruton's tyrosine kinase gene from patients with X-linked
RT   agammaglobulinemia.";
RL   Mol. Med. 3:477-485(1997).
RN   [70]
RP   VARIANTS XLA GLN-288; THR-307; ARG-430; ASP-445; GLY-525; PHE-535; LEU-563
RP   AND PRO-622.
RX   PubMed=9545398; DOI=10.1086/301828;
RA   Conley M.E., Mathias D., Treadaway J., Minegishi Y., Rohrer J.;
RT   "Mutations in btk in patients with presumed X-linked agammaglobulinemia.";
RL   Am. J. Hum. Genet. 62:1034-1043(1998).
RN   [71]
RP   VARIANTS XLA GLU-19; HIS-28; ASN-61; PRO-117; HIS-127; ARG-155; PRO-295;
RP   PHE-369; GLY-372; ARG-414; TYR-506; GLY-521; GLN-525; SER-559; TRP-562;
RP   GLU-594; THR-619; GLY-626 AND HIS-641.
RX   PubMed=9445504; DOI=10.1542/peds.101.2.276;
RA   Holinski-Feder E., Weiss M., Brandau O., Jedele K.B., Nore B.,
RA   Baeckesjoe C.-M., Vihinen M., Hubbard S.R., Belohradsky B.H., Smith C.I.E.,
RA   Meindl A.;
RT   "Mutation screening of the BTK gene in 56 families with X-linked
RT   agammaglobulinemia (XLA): 47 unique mutations without correlation to
RT   clinical course.";
RL   Pediatrics 101:276-284(1998).
RN   [72]
RP   VARIANTS XLA.
RX   PubMed=10220140;
RX   DOI=10.1002/(sici)1098-1004(1999)13:4<280::aid-humu3>3.0.co;2-l;
RA   Vihinen M., Kwan S.-P., Lester T., Ochs H.D., Resnick I., Vaeliaho J.,
RA   Conley M.E., Smith C.I.E.;
RT   "Mutations of the human BTK gene coding for Bruton tyrosine kinase in X-
RT   linked agammaglobulinemia.";
RL   Hum. Mutat. 13:280-285(1999).
RN   [73]
RP   VARIANT XLA PRO-562.
RX   PubMed=10678660;
RX   DOI=10.1002/(sici)1096-8628(20000131)90:3<229::aid-ajmg8>3.0.co;2-q;
RA   Curtis S.K., Hebert M.D., Saha B.K.;
RT   "Twin carriers of X-linked agammaglobulinemia (XLA) due to germline
RT   mutation in the Btk gene.";
RL   Am. J. Med. Genet. 90:229-232(2000).
RN   [74]
RP   VARIANTS XLA SER-39; PRO-512; GLN-512; GLY-544; TYR-578 AND LYS-589.
RX   PubMed=10612838;
RX   DOI=10.1002/(sici)1098-1004(200001)15:1<117::aid-humu26>3.0.co;2-h;
RA   Orlandi P., Ritis K., Moschese V., Angelini F., Arvanitidis K.,
RA   Speletas M., Sideras P., Plebani A., Rossi P.;
RT   "Identification of nine novel mutations in the Bruton's tyrosine kinase
RT   gene in X-linked agammaglobulinaemia patients.";
RL   Hum. Mutat. 15:117-117(2000).
RN   [75]
RP   VARIANTS [LARGE SCALE ANALYSIS] LYS-82 AND LYS-190.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [76]
RP   VARIANT SER-481, AND CHARACTERIZATION OF VARIANT SER-481.
RX   PubMed=24869598; DOI=10.1056/nejmoa1400029;
RA   Woyach J.A., Furman R.R., Liu T.M., Ozer H.G., Zapatka M., Ruppert A.S.,
RA   Xue L., Li D.H., Steggerda S.M., Versele M., Dave S.S., Zhang J.,
RA   Yilmaz A.S., Jaglowski S.M., Blum K.A., Lozanski A., Lozanski G.,
RA   James D.F., Barrientos J.C., Lichter P., Stilgenbauer S., Buggy J.J.,
RA   Chang B.Y., Johnson A.J., Byrd J.C.;
RT   "Resistance mechanisms for the Bruton's tyrosine kinase inhibitor
RT   ibrutinib.";
RL   N. Engl. J. Med. 370:2286-2294(2014).
RN   [77]
RP   CHARACTERIZATION OF VARIANT SER-481.
RX   PubMed=24869597; DOI=10.1056/nejmc1402716;
RA   Furman R.R., Cheng S., Lu P., Setty M., Perez A.R., Perez A.R., Guo A.,
RA   Racchumi J., Xu G., Wu H., Ma J., Steggerda S.M., Coleman M., Leslie C.,
RA   Wang Y.L.;
RT   "Ibrutinib resistance in chronic lymphocytic leukemia.";
RL   N. Engl. J. Med. 370:2352-2354(2014).
RN   [78]
RP   CHARACTERIZATION OF VARIANT SER-481.
RX   PubMed=25189416; DOI=10.1038/leu.2014.263;
RA   Cheng S., Guo A., Lu P., Ma J., Coleman M., Wang Y.L.;
RT   "Functional characterization of BTK(C481S) mutation that confers ibrutinib
RT   resistance: exploration of alternative kinase inhibitors.";
RL   Leukemia 29:895-900(2015).
CC   -!- FUNCTION: Non-receptor tyrosine kinase indispensable for B lymphocyte
CC       development, differentiation and signaling. Binding of antigen to the
CC       B-cell antigen receptor (BCR) triggers signaling that ultimately leads
CC       to B-cell activation. After BCR engagement and activation at the plasma
CC       membrane, phosphorylates PLCG2 at several sites, igniting the
CC       downstream signaling pathway through calcium mobilization, followed by
CC       activation of the protein kinase C (PKC) family members. PLCG2
CC       phosphorylation is performed in close cooperation with the adapter
CC       protein B-cell linker protein BLNK. BTK acts as a platform to bring
CC       together a diverse array of signaling proteins and is implicated in
CC       cytokine receptor signaling pathways. Plays an important role in the
CC       function of immune cells of innate as well as adaptive immunity, as a
CC       component of the Toll-like receptors (TLR) pathway. The TLR pathway
CC       acts as a primary surveillance system for the detection of pathogens
CC       and are crucial to the activation of host defense. Especially, is a
CC       critical molecule in regulating TLR9 activation in splenic B-cells.
CC       Within the TLR pathway, induces tyrosine phosphorylation of TIRAP which
CC       leads to TIRAP degradation. BTK also plays a critical role in
CC       transcription regulation. Induces the activity of NF-kappa-B, which is
CC       involved in regulating the expression of hundreds of genes. BTK is
CC       involved on the signaling pathway linking TLR8 and TLR9 to NF-kappa-B.
CC       Transiently phosphorylates transcription factor GTF2I on tyrosine
CC       residues in response to BCR. GTF2I then translocates to the nucleus to
CC       bind regulatory enhancer elements to modulate gene expression. ARID3A
CC       and NFAT are other transcriptional target of BTK. BTK is required for
CC       the formation of functional ARID3A DNA-binding complexes. There is
CC       however no evidence that BTK itself binds directly to DNA. BTK has a
CC       dual role in the regulation of apoptosis. {ECO:0000269|PubMed:11606584,
CC       ECO:0000269|PubMed:16415872, ECO:0000269|PubMed:16517732,
CC       ECO:0000269|PubMed:16738337, ECO:0000269|PubMed:17932028,
CC       ECO:0000269|PubMed:9012831}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.2;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC       Note=Binds 1 zinc ion per subunit.;
CC   -!- ACTIVITY REGULATION: Activated by phosphorylation. In primary B
CC       lymphocytes, is almost always non-phosphorylated and is thus
CC       catalytically inactive. Stimulation of TLR8 and TLR9 causes BTK
CC       activation. As a negative feedback mechanism to fine-tune BCR
CC       signaling, activated PRKCB down-modulates BTK function via direct
CC       phosphorylation of BTK at Ser-180, resulting in translocation of BTK
CC       back to the cytoplasmic fraction. PIN1, SH3BP5, and IBTK were also
CC       identified as BTK activity inhibitors. Interaction with CAV1 leads to
CC       dramatic down-regulation of the kinase activity of BTK. LFM-13A is a
CC       specific inhibitor of BTK. Dasatinib, a cancer drug acting as a
CC       tyrosine kinase inhibitor, also blocks BTK activity.
CC       {ECO:0000269|PubMed:10339589, ECO:0000269|PubMed:11577348,
CC       ECO:0000269|PubMed:11598012, ECO:0000269|PubMed:11751885,
CC       ECO:0000269|PubMed:16415872, ECO:0000269|PubMed:16644721,
CC       ECO:0000269|PubMed:17932028, ECO:0000269|PubMed:8630736}.
CC   -!- SUBUNIT: Binds GTF2I through the PH domain. Interacts with SH3BP5 via
CC       the SH3 domain. Interacts with IBTK via its PH domain. Interacts with
CC       ARID3A, CAV1, FASLG, PIN1, TLR8 and TLR9. {ECO:0000269|PubMed:10196129,
CC       ECO:0000269|PubMed:10339589, ECO:0000269|PubMed:11577348,
CC       ECO:0000269|PubMed:11751885, ECO:0000269|PubMed:16644721,
CC       ECO:0000269|PubMed:16738337, ECO:0000269|PubMed:17932028,
CC       ECO:0000269|PubMed:19807924, ECO:0000269|PubMed:20052711,
CC       ECO:0000269|PubMed:21280133, ECO:0000269|PubMed:9218782,
CC       ECO:0000269|PubMed:9571151, ECO:0000269|Ref.46, ECO:0000269|Ref.47}.
CC   -!- INTERACTION:
CC       Q06187; Q13444: ADAM15; NbExp=2; IntAct=EBI-624835, EBI-77818;
CC       Q06187; Q99856: ARID3A; NbExp=3; IntAct=EBI-624835, EBI-5458244;
CC       Q06187; Q8WV28: BLNK; NbExp=2; IntAct=EBI-624835, EBI-2623522;
CC       Q06187; Q06187: BTK; NbExp=2; IntAct=EBI-624835, EBI-624835;
CC       Q06187; P78347: GTF2I; NbExp=6; IntAct=EBI-624835, EBI-359622;
CC       Q06187; P08238: HSP90AB1; NbExp=2; IntAct=EBI-624835, EBI-352572;
CC       Q06187; P21145: MAL; NbExp=5; IntAct=EBI-624835, EBI-3932027;
CC       Q06187; P50222: MEOX2; NbExp=3; IntAct=EBI-624835, EBI-748397;
CC       Q06187; Q04759: PRKCQ; NbExp=2; IntAct=EBI-624835, EBI-374762;
CC       Q06187; O60239: SH3BP5; NbExp=4; IntAct=EBI-624835, EBI-624860;
CC       Q06187; P42768: WAS; NbExp=4; IntAct=EBI-624835, EBI-346375;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cell membrane; Peripheral membrane
CC       protein. Nucleus. Note=In steady state, BTK is predominantly cytosolic.
CC       Following B-cell receptor (BCR) engagement by antigen, translocates to
CC       the plasma membrane through its PH domain. Plasma membrane localization
CC       is a critical step in the activation of BTK. A fraction of BTK also
CC       shuttles between the nucleus and the cytoplasm, and nuclear export is
CC       mediated by the nuclear export receptor CRM1.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage; Named isoforms=2;
CC       Name=BTK-A;
CC         IsoId=Q06187-1; Sequence=Displayed;
CC       Name=BTK-C;
CC         IsoId=Q06187-2; Sequence=VSP_053838;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in B-lymphocytes.
CC   -!- DOMAIN: The PH domain mediates the binding to inositol polyphosphate
CC       and phosphoinositides, leading to its targeting to the plasma membrane.
CC       It is extended in the BTK kinase family by a region designated the TH
CC       (Tec homology) domain, which consists of about 80 residues preceding
CC       the SH3 domain. {ECO:0000269|PubMed:10196129,
CC       ECO:0000269|PubMed:10196179, ECO:0000269|PubMed:11751885,
CC       ECO:0000269|PubMed:8070576}.
CC   -!- PTM: Following B-cell receptor (BCR) engagement, translocates to the
CC       plasma membrane where it gets phosphorylated at Tyr-551 by LYN and SYK.
CC       Phosphorylation at Tyr-551 is followed by autophosphorylation of Tyr-
CC       223 which may create a docking site for a SH2 containing protein.
CC       Phosphorylation at Ser-180 by PRKCB, leads in translocation of BTK back
CC       to the cytoplasmic fraction. Phosphorylation at Ser-21 and Ser-115
CC       creates a binding site for PIN1 at these Ser-Pro motifs, and promotes
CC       it's recruitment. {ECO:0000269|PubMed:11598012,
CC       ECO:0000269|PubMed:12573241, ECO:0000269|PubMed:15375214,
CC       ECO:0000269|PubMed:16644721, ECO:0000269|PubMed:17932028,
CC       ECO:0000269|PubMed:8630736, ECO:0000269|PubMed:9012831}.
CC   -!- DISEASE: X-linked agammaglobulinemia (XLA) [MIM:300755]: Humoral
CC       immunodeficiency disease which results in developmental defects in the
CC       maturation pathway of B-cells. Affected boys have normal levels of pre-
CC       B-cells in their bone marrow but virtually no circulating mature B-
CC       lymphocytes. This results in a lack of immunoglobulins of all classes
CC       and leads to recurrent bacterial infections like otitis,
CC       conjunctivitis, dermatitis, sinusitis in the first few years of life,
CC       or even some patients present overwhelming sepsis or meningitis,
CC       resulting in death in a few hours. Treatment in most cases is by
CC       infusion of intravenous immunoglobulin. {ECO:0000269|PubMed:10220140,
CC       ECO:0000269|PubMed:10612838, ECO:0000269|PubMed:10678660,
CC       ECO:0000269|PubMed:7627183, ECO:0000269|PubMed:7633420,
CC       ECO:0000269|PubMed:7633429, ECO:0000269|PubMed:7711734,
CC       ECO:0000269|PubMed:7809124, ECO:0000269|PubMed:7849006,
CC       ECO:0000269|PubMed:7849697, ECO:0000269|PubMed:7849721,
CC       ECO:0000269|PubMed:7880320, ECO:0000269|PubMed:7897635,
CC       ECO:0000269|PubMed:8013627, ECO:0000269|PubMed:8162018,
CC       ECO:0000269|PubMed:8162056, ECO:0000269|PubMed:8594569,
CC       ECO:0000269|PubMed:8634718, ECO:0000269|PubMed:8695804,
CC       ECO:0000269|PubMed:8723128, ECO:0000269|PubMed:8834236,
CC       ECO:0000269|PubMed:9016530, ECO:0000269|PubMed:9260159,
CC       ECO:0000269|PubMed:9280283, ECO:0000269|PubMed:9445504,
CC       ECO:0000269|PubMed:9545398}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Growth hormone deficiency, isolated, 3, with
CC       agammaglobulinemia (IGHD3) [MIM:307200]: An X-linked recessive disorder
CC       characterized by growth hormone deficiency, short stature, delayed bone
CC       age, agammaglobulinemia with markedly reduced numbers of B cells, and
CC       good response to treatment with growth hormone.
CC       {ECO:0000269|PubMed:8013627}. Note=The disease may be caused by
CC       variants affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: [Isoform BTK-C]: Produced by alternative promoter usage.
CC       Predominant form in many tumor cells where it may function as an anti-
CC       apoptotic cell survival factor. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. TEC subfamily. {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/BTKID851chXq22.html";
CC   -!- WEB RESOURCE: Name=BTKbase; Note=BTK mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/BTKbase/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X58957; CAA41728.1; -; mRNA.
DR   EMBL; U10087; AAB60639.1; -; Genomic_DNA.
DR   EMBL; U10084; AAB60639.1; JOINED; Genomic_DNA.
DR   EMBL; U10085; AAB60639.1; JOINED; Genomic_DNA.
DR   EMBL; U10086; AAB60639.1; JOINED; Genomic_DNA.
DR   EMBL; L31572; AAA61479.1; -; Genomic_DNA.
DR   EMBL; L31557; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31558; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31559; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31561; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31563; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31564; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31565; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31566; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31567; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31568; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31569; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31570; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; L31571; AAA61479.1; JOINED; Genomic_DNA.
DR   EMBL; U13433; AAC51347.1; -; Genomic_DNA.
DR   EMBL; U13410; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13412; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13413; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13414; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13415; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13416; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13417; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13422; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13423; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13424; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13425; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13427; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13428; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13429; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13430; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13431; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U13432; AAC51347.1; JOINED; Genomic_DNA.
DR   EMBL; U78027; AAB64205.1; -; Genomic_DNA.
DR   EMBL; AK314382; BAG37008.1; -; mRNA.
DR   EMBL; AL035422; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC109079; AAI09080.1; -; mRNA.
DR   EMBL; BC109080; AAI09081.1; -; mRNA.
DR   CCDS; CCDS14482.1; -. [Q06187-1]
DR   CCDS; CCDS76003.1; -. [Q06187-2]
DR   PIR; I37212; A45184.
DR   RefSeq; NP_000052.1; NM_000061.2. [Q06187-1]
DR   RefSeq; NP_001274273.1; NM_001287344.1. [Q06187-2]
DR   RefSeq; NP_001274274.1; NM_001287345.1.
DR   PDB; 1AWW; NMR; -; A=212-275.
DR   PDB; 1AWX; NMR; -; A=212-275.
DR   PDB; 1B55; X-ray; 2.40 A; A/B=2-170.
DR   PDB; 1BTK; X-ray; 1.60 A; A/B=2-170.
DR   PDB; 1BWN; X-ray; 2.10 A; A/B=2-170.
DR   PDB; 1K2P; X-ray; 2.10 A; A/B=397-659.
DR   PDB; 1QLY; NMR; -; A=216-273.
DR   PDB; 2GE9; NMR; -; A=270-387.
DR   PDB; 2Z0P; X-ray; 2.58 A; A/B/C/D=2-170.
DR   PDB; 3GEN; X-ray; 1.60 A; A=382-659.
DR   PDB; 3K54; X-ray; 1.94 A; A=382-659.
DR   PDB; 3OCS; X-ray; 1.80 A; A=393-656.
DR   PDB; 3OCT; X-ray; 1.95 A; A=393-656.
DR   PDB; 3P08; X-ray; 2.30 A; A/B=393-659.
DR   PDB; 3PIX; X-ray; 1.85 A; A=387-659.
DR   PDB; 3PIY; X-ray; 2.55 A; A=387-659.
DR   PDB; 3PIZ; X-ray; 2.21 A; A=387-659.
DR   PDB; 3PJ1; X-ray; 2.00 A; A=387-659.
DR   PDB; 3PJ2; X-ray; 1.75 A; A=387-659.
DR   PDB; 3PJ3; X-ray; 1.85 A; A=387-659.
DR   PDB; 4NWM; X-ray; 2.03 A; A/B=396-657.
DR   PDB; 4OT5; X-ray; 1.55 A; A=378-659.
DR   PDB; 4OT6; X-ray; 2.05 A; A=378-659.
DR   PDB; 4OTF; X-ray; 1.95 A; A=393-657.
DR   PDB; 4OTQ; X-ray; 1.55 A; A=378-659.
DR   PDB; 4OTR; X-ray; 1.95 A; A=378-659.
DR   PDB; 4RFY; X-ray; 1.70 A; A=378-659.
DR   PDB; 4RFZ; X-ray; 1.17 A; A=378-659.
DR   PDB; 4RG0; X-ray; 2.50 A; A=378-659.
DR   PDB; 4RX5; X-ray; 1.36 A; A=393-657.
DR   PDB; 4YHF; X-ray; 2.20 A; A/B=382-659.
DR   PDB; 4Z3V; X-ray; 1.60 A; A=382-659.
DR   PDB; 4ZLY; X-ray; 1.65 A; A=389-658.
DR   PDB; 4ZLZ; X-ray; 2.00 A; A=389-658.
DR   PDB; 5BPY; X-ray; 2.31 A; A/B=396-659.
DR   PDB; 5BQ0; X-ray; 1.57 A; A=382-659.
DR   PDB; 5FBN; X-ray; 1.80 A; C/D=389-659.
DR   PDB; 5FBO; X-ray; 1.89 A; A=389-659.
DR   PDB; 5J87; X-ray; 1.59 A; A/B/C/D=385-658.
DR   PDB; 5JRS; X-ray; 1.97 A; A/B=396-659.
DR   PDB; 5KUP; X-ray; 1.39 A; A=393-657.
DR   PDB; 5P9F; X-ray; 1.71 A; A=382-659.
DR   PDB; 5P9G; X-ray; 1.75 A; A=382-659.
DR   PDB; 5P9H; X-ray; 1.95 A; A=382-659.
DR   PDB; 5P9I; X-ray; 1.11 A; A=382-659.
DR   PDB; 5P9J; X-ray; 1.08 A; A=382-659.
DR   PDB; 5P9K; X-ray; 1.28 A; A=382-659.
DR   PDB; 5P9L; X-ray; 1.25 A; A=382-659.
DR   PDB; 5P9M; X-ray; 1.41 A; A=382-659.
DR   PDB; 5T18; X-ray; 1.50 A; A=396-659.
DR   PDB; 5U9D; X-ray; 1.33 A; A=389-659.
DR   PDB; 5VFI; X-ray; 1.59 A; A=389-659.
DR   PDB; 5VGO; X-ray; 1.62 A; A=393-657.
DR   PDB; 5XYZ; X-ray; 2.64 A; A/B=393-656.
DR   PDB; 5ZZ4; X-ray; 2.90 A; A/B/C/D/E/F=393-656.
DR   PDB; 6AUA; X-ray; 1.66 A; A=394-656.
DR   PDB; 6AUB; X-ray; 1.65 A; A=395-657.
DR   PDB; 6BIK; X-ray; 1.90 A; A=392-657.
DR   PDB; 6BKE; X-ray; 1.95 A; A=392-657.
DR   PDB; 6BKH; X-ray; 1.79 A; A=392-657.
DR   PDB; 6BKW; X-ray; 1.50 A; A=392-657.
DR   PDB; 6BLN; X-ray; 1.30 A; A=392-657.
DR   PDB; 6DI0; X-ray; 1.30 A; A=389-659.
DR   PDB; 6DI1; X-ray; 1.10 A; A=389-659.
DR   PDB; 6DI3; X-ray; 2.00 A; A=389-659.
DR   PDB; 6DI5; X-ray; 1.42 A; A=389-659.
DR   PDB; 6DI9; X-ray; 1.25 A; A=389-659.
DR   PDB; 6E4F; X-ray; 1.15 A; A=387-659.
DR   PDB; 6EP9; X-ray; 2.01 A; A=378-659.
DR   PDB; 6HRP; X-ray; 1.12 A; A=378-659.
DR   PDB; 6HRT; X-ray; 1.36 A; A=378-659.
DR   PDB; 6HTF; X-ray; 2.10 A; A=271-383.
DR   PDB; 6J6M; X-ray; 1.25 A; A=393-659.
DR   PDB; 6N9P; X-ray; 2.23 A; A=389-659.
DR   PDB; 6NFH; X-ray; 1.40 A; A=389-659.
DR   PDB; 6NFI; X-ray; 2.41 A; A=392-659.
DR   PDB; 6NZM; X-ray; 1.72 A; A/D=382-659.
DR   PDB; 6O8I; X-ray; 1.42 A; A=391-659.
DR   PDB; 6OMU; X-ray; 1.41 A; A=389-659.
DR   PDB; 6S90; X-ray; 1.82 A; A/B=393-658.
DR   PDB; 6TFP; X-ray; 2.00 A; A/B/C/D/E=385-659.
DR   PDB; 6TSE; X-ray; 1.41 A; A/B=2-170.
DR   PDB; 6TT2; X-ray; 1.36 A; A/B=2-170.
DR   PDB; 6TUH; X-ray; 2.25 A; A/B/C/D=2-170.
DR   PDB; 6TVN; X-ray; 2.31 A; A/B/C/D=2-170.
DR   PDB; 6VXQ; X-ray; 1.40 A; A=371-659.
DR   PDB; 6W06; X-ray; 1.55 A; A=371-659.
DR   PDB; 6W07; X-ray; 1.51 A; A=371-659.
DR   PDB; 6W7O; X-ray; 2.17 A; A/B=384-659.
DR   PDB; 6W8I; X-ray; 3.80 A; A/B/C=384-659.
DR   PDB; 6X3N; X-ray; 1.95 A; A=389-659.
DR   PDB; 6X3O; X-ray; 1.90 A; A/B=389-659.
DR   PDB; 6X3P; X-ray; 1.34 A; A=389-659.
DR   PDB; 6XE4; X-ray; 1.60 A; A=393-657.
DR   PDB; 6YYF; X-ray; 1.93 A; A/B=2-170.
DR   PDB; 6YYG; X-ray; 1.95 A; A/B/C/D=2-170.
DR   PDB; 6YYK; X-ray; 2.04 A; A/B=2-170.
DR   PDB; 7KXL; X-ray; 1.84 A; A=392-659.
DR   PDB; 7KXM; X-ray; 1.33 A; A=389-659.
DR   PDB; 7KXN; X-ray; 1.34 A; A=393-659.
DR   PDB; 7KXO; X-ray; 1.94 A; A=393-659.
DR   PDB; 7KXP; X-ray; 1.83 A; A=389-659.
DR   PDB; 7KXQ; X-ray; 1.38 A; A=390-659.
DR   PDB; 7LTY; X-ray; 1.69 A; A=393-659.
DR   PDB; 7LTZ; X-ray; 1.53 A; A=393-659.
DR   PDB; 7N5O; X-ray; 1.25 A; A=382-659.
DR   PDB; 7N5R; X-ray; 1.55 A; A=382-659.
DR   PDB; 7N5X; X-ray; 1.60 A; A=382-659.
DR   PDB; 7N5Y; X-ray; 1.85 A; A=382-659.
DR   PDB; 7R60; X-ray; 1.94 A; A=389-659.
DR   PDB; 7R61; X-ray; 1.52 A; A=390-659.
DR   PDBsum; 1AWW; -.
DR   PDBsum; 1AWX; -.
DR   PDBsum; 1B55; -.
DR   PDBsum; 1BTK; -.
DR   PDBsum; 1BWN; -.
DR   PDBsum; 1K2P; -.
DR   PDBsum; 1QLY; -.
DR   PDBsum; 2GE9; -.
DR   PDBsum; 2Z0P; -.
DR   PDBsum; 3GEN; -.
DR   PDBsum; 3K54; -.
DR   PDBsum; 3OCS; -.
DR   PDBsum; 3OCT; -.
DR   PDBsum; 3P08; -.
DR   PDBsum; 3PIX; -.
DR   PDBsum; 3PIY; -.
DR   PDBsum; 3PIZ; -.
DR   PDBsum; 3PJ1; -.
DR   PDBsum; 3PJ2; -.
DR   PDBsum; 3PJ3; -.
DR   PDBsum; 4NWM; -.
DR   PDBsum; 4OT5; -.
DR   PDBsum; 4OT6; -.
DR   PDBsum; 4OTF; -.
DR   PDBsum; 4OTQ; -.
DR   PDBsum; 4OTR; -.
DR   PDBsum; 4RFY; -.
DR   PDBsum; 4RFZ; -.
DR   PDBsum; 4RG0; -.
DR   PDBsum; 4RX5; -.
DR   PDBsum; 4YHF; -.
DR   PDBsum; 4Z3V; -.
DR   PDBsum; 4ZLY; -.
DR   PDBsum; 4ZLZ; -.
DR   PDBsum; 5BPY; -.
DR   PDBsum; 5BQ0; -.
DR   PDBsum; 5FBN; -.
DR   PDBsum; 5FBO; -.
DR   PDBsum; 5J87; -.
DR   PDBsum; 5JRS; -.
DR   PDBsum; 5KUP; -.
DR   PDBsum; 5P9F; -.
DR   PDBsum; 5P9G; -.
DR   PDBsum; 5P9H; -.
DR   PDBsum; 5P9I; -.
DR   PDBsum; 5P9J; -.
DR   PDBsum; 5P9K; -.
DR   PDBsum; 5P9L; -.
DR   PDBsum; 5P9M; -.
DR   PDBsum; 5T18; -.
DR   PDBsum; 5U9D; -.
DR   PDBsum; 5VFI; -.
DR   PDBsum; 5VGO; -.
DR   PDBsum; 5XYZ; -.
DR   PDBsum; 5ZZ4; -.
DR   PDBsum; 6AUA; -.
DR   PDBsum; 6AUB; -.
DR   PDBsum; 6BIK; -.
DR   PDBsum; 6BKE; -.
DR   PDBsum; 6BKH; -.
DR   PDBsum; 6BKW; -.
DR   PDBsum; 6BLN; -.
DR   PDBsum; 6DI0; -.
DR   PDBsum; 6DI1; -.
DR   PDBsum; 6DI3; -.
DR   PDBsum; 6DI5; -.
DR   PDBsum; 6DI9; -.
DR   PDBsum; 6E4F; -.
DR   PDBsum; 6EP9; -.
DR   PDBsum; 6HRP; -.
DR   PDBsum; 6HRT; -.
DR   PDBsum; 6HTF; -.
DR   PDBsum; 6J6M; -.
DR   PDBsum; 6N9P; -.
DR   PDBsum; 6NFH; -.
DR   PDBsum; 6NFI; -.
DR   PDBsum; 6NZM; -.
DR   PDBsum; 6O8I; -.
DR   PDBsum; 6OMU; -.
DR   PDBsum; 6S90; -.
DR   PDBsum; 6TFP; -.
DR   PDBsum; 6TSE; -.
DR   PDBsum; 6TT2; -.
DR   PDBsum; 6TUH; -.
DR   PDBsum; 6TVN; -.
DR   PDBsum; 6VXQ; -.
DR   PDBsum; 6W06; -.
DR   PDBsum; 6W07; -.
DR   PDBsum; 6W7O; -.
DR   PDBsum; 6W8I; -.
DR   PDBsum; 6X3N; -.
DR   PDBsum; 6X3O; -.
DR   PDBsum; 6X3P; -.
DR   PDBsum; 6XE4; -.
DR   PDBsum; 6YYF; -.
DR   PDBsum; 6YYG; -.
DR   PDBsum; 6YYK; -.
DR   PDBsum; 7KXL; -.
DR   PDBsum; 7KXM; -.
DR   PDBsum; 7KXN; -.
DR   PDBsum; 7KXO; -.
DR   PDBsum; 7KXP; -.
DR   PDBsum; 7KXQ; -.
DR   PDBsum; 7LTY; -.
DR   PDBsum; 7LTZ; -.
DR   PDBsum; 7N5O; -.
DR   PDBsum; 7N5R; -.
DR   PDBsum; 7N5X; -.
DR   PDBsum; 7N5Y; -.
DR   PDBsum; 7R60; -.
DR   PDBsum; 7R61; -.
DR   AlphaFoldDB; Q06187; -.
DR   BMRB; Q06187; -.
DR   SASBDB; Q06187; -.
DR   SMR; Q06187; -.
DR   BioGRID; 107160; 102.
DR   CORUM; Q06187; -.
DR   DIP; DIP-34071N; -.
DR   ELM; Q06187; -.
DR   IntAct; Q06187; 60.
DR   MINT; Q06187; -.
DR   STRING; 9606.ENSP00000483570; -.
DR   BindingDB; Q06187; -.
DR   ChEMBL; CHEMBL5251; -.
DR   DrugBank; DB15327; Abivertinib.
DR   DrugBank; DB11703; Acalabrutinib.
DR   DrugBank; DB01254; Dasatinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB09053; Ibrutinib.
DR   DrugBank; DB01863; Inositol 1,3,4,5-Tetrakisphosphate.
DR   DrugBank; DB16657; Vecabrutinib.
DR   DrugBank; DB05204; XL418.
DR   DrugBank; DB15035; Zanubrutinib.
DR   DrugCentral; Q06187; -.
DR   GuidetoPHARMACOLOGY; 1948; -.
DR   iPTMnet; Q06187; -.
DR   PhosphoSitePlus; Q06187; -.
DR   BioMuta; BTK; -.
DR   DMDM; 547759; -.
DR   EPD; Q06187; -.
DR   jPOST; Q06187; -.
DR   MassIVE; Q06187; -.
DR   MaxQB; Q06187; -.
DR   PaxDb; Q06187; -.
DR   PeptideAtlas; Q06187; -.
DR   PRIDE; Q06187; -.
DR   ProteomicsDB; 58419; -. [Q06187-1]
DR   ABCD; Q06187; 7 sequenced antibodies.
DR   Antibodypedia; 699; 1328 antibodies from 46 providers.
DR   CPTC; Q06187; 1 antibody.
DR   DNASU; 695; -.
DR   Ensembl; ENST00000308731.8; ENSP00000308176.8; ENSG00000010671.18. [Q06187-1]
DR   Ensembl; ENST00000621635.4; ENSP00000483570.1; ENSG00000010671.18. [Q06187-2]
DR   Ensembl; ENST00000695614.1; ENSP00000512053.1; ENSG00000010671.18. [Q06187-1]
DR   Ensembl; ENST00000695615.1; ENSP00000512054.1; ENSG00000010671.18. [Q06187-1]
DR   GeneID; 695; -.
DR   KEGG; hsa:695; -.
DR   MANE-Select; ENST00000308731.8; ENSP00000308176.8; NM_000061.3; NP_000052.1.
DR   UCSC; uc004ehg.3; human. [Q06187-1]
DR   CTD; 695; -.
DR   DisGeNET; 695; -.
DR   GeneCards; BTK; -.
DR   GeneReviews; BTK; -.
DR   HGNC; HGNC:1133; BTK.
DR   HPA; ENSG00000010671; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MalaCards; BTK; -.
DR   MIM; 300300; gene.
DR   MIM; 300755; phenotype.
DR   MIM; 307200; phenotype.
DR   neXtProt; NX_Q06187; -.
DR   OpenTargets; ENSG00000010671; -.
DR   Orphanet; 632; Short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinemia.
DR   Orphanet; 47; X-linked agammaglobulinemia.
DR   PharmGKB; PA25454; -.
DR   VEuPathDB; HostDB:ENSG00000010671; -.
DR   eggNOG; KOG0197; Eukaryota.
DR   GeneTree; ENSGT00940000158469; -.
DR   InParanoid; Q06187; -.
DR   OrthoDB; 1047190at2759; -.
DR   PhylomeDB; Q06187; -.
DR   TreeFam; TF351634; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   PathwayCommons; Q06187; -.
DR   Reactome; R-HSA-1236974; ER-Phagosome pathway.
DR   Reactome; R-HSA-166058; MyD88:MAL(TIRAP) cascade initiated on plasma membrane.
DR   Reactome; R-HSA-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-HSA-2424491; DAP12 signaling.
DR   Reactome; R-HSA-2871809; FCERI mediated Ca+2 mobilization.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-5602498; MyD88 deficiency (TLR2/4).
DR   Reactome; R-HSA-5603041; IRAK4 deficiency (TLR2/4).
DR   Reactome; R-HSA-5663213; RHO GTPases Activate WASPs and WAVEs.
DR   Reactome; R-HSA-8964315; G beta:gamma signalling through BTK.
DR   Reactome; R-HSA-9664422; FCGR3A-mediated phagocytosis.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   Reactome; R-HSA-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   SignaLink; Q06187; -.
DR   SIGNOR; Q06187; -.
DR   BioGRID-ORCS; 695; 17 hits in 740 CRISPR screens.
DR   ChiTaRS; BTK; human.
DR   EvolutionaryTrace; Q06187; -.
DR   GeneWiki; Bruton%27s_tyrosine_kinase; -.
DR   GenomeRNAi; 695; -.
DR   Pharos; Q06187; Tclin.
DR   PRO; PR:Q06187; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q06187; protein.
DR   Bgee; ENSG00000010671; Expressed in monocyte and 138 other tissues.
DR   ExpressionAtlas; Q06187; baseline and differential.
DR   Genevisible; Q06187; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:HGNC-UCL.
DR   GO; GO:0005634; C:nucleus; TAS:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; TAS:HGNC-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IDA:ARUK-UCL.
DR   GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; IDA:UniProtKB.
DR   GO; GO:0016004; F:phospholipase activator activity; IDA:ARUK-UCL.
DR   GO; GO:0043274; F:phospholipase binding; IPI:ARUK-UCL.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0002250; P:adaptive immune response; TAS:UniProtKB.
DR   GO; GO:0097190; P:apoptotic signaling pathway; TAS:ProtInc.
DR   GO; GO:0042113; P:B cell activation; TAS:UniProtKB.
DR   GO; GO:0002344; P:B cell affinity maturation; IEA:Ensembl.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IDA:ARUK-UCL.
DR   GO; GO:0019722; P:calcium-mediated signaling; TAS:HGNC-UCL.
DR   GO; GO:0048469; P:cell maturation; IEA:Ensembl.
DR   GO; GO:0098761; P:cellular response to interleukin-7; IEA:Ensembl.
DR   GO; GO:0071226; P:cellular response to molecule of fungal origin; IEA:Ensembl.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; IEA:Ensembl.
DR   GO; GO:1990959; P:eosinophil homeostasis; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0002553; P:histamine secretion by mast cell; IEA:Ensembl.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; TAS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:ARUK-UCL.
DR   GO; GO:0007498; P:mesoderm development; TAS:ProtInc.
DR   GO; GO:0061516; P:monocyte proliferation; IEA:Ensembl.
DR   GO; GO:0002755; P:MyD88-dependent toll-like receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0030889; P:negative regulation of B cell proliferation; IEA:Ensembl.
DR   GO; GO:0032693; P:negative regulation of interleukin-10 production; IEA:Ensembl.
DR   GO; GO:0001780; P:neutrophil homeostasis; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IEA:Ensembl.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:ARUK-UCL.
DR   GO; GO:0045579; P:positive regulation of B cell differentiation; TAS:UniProtKB.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IEA:Ensembl.
DR   GO; GO:0002639; P:positive regulation of immunoglobulin production; IEA:Ensembl.
DR   GO; GO:0150153; P:positive regulation of interleukin-17A production; IEA:Ensembl.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IEA:Ensembl.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; TAS:UniProtKB.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; IEA:Ensembl.
DR   GO; GO:1901647; P:positive regulation of synoviocyte proliferation; IEA:Ensembl.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0001812; P:positive regulation of type I hypersensitivity; IEA:Ensembl.
DR   GO; GO:0001805; P:positive regulation of type III hypersensitivity; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:HGNC-UCL.
DR   GO; GO:0030167; P:proteoglycan catabolic process; IEA:Ensembl.
DR   GO; GO:0002902; P:regulation of B cell apoptotic process; TAS:UniProtKB.
DR   GO; GO:0002721; P:regulation of B cell cytokine production; TAS:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   CDD; cd11906; SH3_BTK; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR035574; BTK_SH3.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR001562; Znf_Btk_motif.
DR   Pfam; PF00779; BTK; 1.
DR   Pfam; PF00169; PH; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF00018; SH3_1; 1.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   PRINTS; PR00452; SH3DOMAIN.
DR   PRINTS; PR00402; TECBTKDOMAIN.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00107; BTK; 1.
DR   SMART; SM00233; PH; 1.
DR   SMART; SM00252; SH2; 1.
DR   SMART; SM00326; SH3; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF50044; SSF50044; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS50001; SH2; 1.
DR   PROSITE; PS50002; SH3; 1.
DR   PROSITE; PS51113; ZF_BTK; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Adaptive immunity; Alternative promoter usage;
KW   Apoptosis; ATP-binding; Cell membrane; Cytoplasm;
KW   Direct protein sequencing; Disease variant; Dwarfism; Immunity;
KW   Innate immunity; Kinase; Lipid-binding; Membrane; Metal-binding;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   SH2 domain; SH3 domain; Transcription; Transcription regulation;
KW   Transferase; Tyrosine-protein kinase; Zinc; Zinc-finger.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.11, ECO:0007744|PubMed:25944712"
FT   CHAIN           2..659
FT                   /note="Tyrosine-protein kinase BTK"
FT                   /id="PRO_0000088065"
FT   DOMAIN          3..133
FT                   /note="PH"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00145"
FT   DOMAIN          214..274
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          281..377
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          402..655
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ZN_FING         135..171
FT                   /note="Btk-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00432"
FT   REGION          12..24
FT                   /note="Inositol-(1,3,4,5)-tetrakisphosphate 1-binding"
FT   REGION          171..210
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           581..588
FT                   /note="CAV1-binding"
FT   ACT_SITE        521
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         26
FT                   /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:57895"
FT                   /evidence="ECO:0000269|PubMed:10196129"
FT   BINDING         28
FT                   /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:57895"
FT                   /evidence="ECO:0000269|PubMed:10196129"
FT   BINDING         39
FT                   /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:57895"
FT                   /evidence="ECO:0000269|PubMed:10196129"
FT   BINDING         53
FT                   /ligand="1D-myo-inositol 1,3,4,5-tetrakisphosphate"
FT                   /ligand_id="ChEBI:CHEBI:57895"
FT                   /evidence="ECO:0000269|PubMed:10196129"
FT   BINDING         143
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00432,
FT                   ECO:0000269|PubMed:10196129, ECO:0000269|PubMed:9218782,
FT                   ECO:0000269|Ref.47"
FT   BINDING         154
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00432,
FT                   ECO:0000269|PubMed:10196129, ECO:0000269|PubMed:9218782,
FT                   ECO:0000269|Ref.47"
FT   BINDING         155
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00432,
FT                   ECO:0000269|PubMed:10196129, ECO:0000269|PubMed:9218782,
FT                   ECO:0000269|Ref.47"
FT   BINDING         165
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00432,
FT                   ECO:0000269|PubMed:10196129, ECO:0000269|PubMed:9218782,
FT                   ECO:0000269|Ref.47"
FT   BINDING         408..416
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         430
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         474..477
FT                   /ligand="clofedanol"
FT                   /ligand_id="ChEBI:CHEBI:187895"
FT                   /ligand_note="inhibitor"
FT                   /evidence="ECO:0000269|PubMed:21280133,
FT                   ECO:0007744|PDB:3PIY"
FT   BINDING         474..477
FT                   /ligand="dasatinib"
FT                   /ligand_id="ChEBI:CHEBI:190514"
FT                   /ligand_note="inhibitor"
FT                   /evidence="ECO:0000269|PubMed:20052711,
FT                   ECO:0007744|PDB:3K54, ECO:0007744|PDB:3OCT"
FT   BINDING         542
FT                   /ligand="clofedanol"
FT                   /ligand_id="ChEBI:CHEBI:187895"
FT                   /ligand_note="inhibitor"
FT                   /evidence="ECO:0000269|PubMed:21280133,
FT                   ECO:0007744|PDB:3PIY"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|Ref.11, ECO:0007744|PubMed:25944712"
FT   MOD_RES         21
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16644721"
FT   MOD_RES         40
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P35991"
FT   MOD_RES         55
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         115
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:16644721"
FT   MOD_RES         180
FT                   /note="Phosphoserine; by PKC/PRKCB"
FT                   /evidence="ECO:0000269|PubMed:11598012"
FT   MOD_RES         191
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         223
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:12573241,
FT                   ECO:0000269|PubMed:17932028, ECO:0000269|PubMed:8630736,
FT                   ECO:0000269|PubMed:9012831, ECO:0007744|PubMed:23186163"
FT   MOD_RES         344
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P35991"
FT   MOD_RES         361
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   MOD_RES         551
FT                   /note="Phosphotyrosine; by LYN and SYK"
FT                   /evidence="ECO:0000269|PubMed:8630736,
FT                   ECO:0000269|PubMed:9012831"
FT   MOD_RES         604
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         617
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:15375214"
FT   MOD_RES         623
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15375214"
FT   MOD_RES         659
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195"
FT   VAR_SEQ         1
FT                   /note="M -> MASWSIQQMVIGCPLCGRHCSGGEHTGELQKEEAM (in isoform
FT                   BTK-C)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053838"
FT   VARIANT         11
FT                   /note="L -> P (in XLA; dbSNP:rs1603020228)"
FT                   /id="VAR_006216"
FT   VARIANT         12
FT                   /note="K -> R (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8695804"
FT                   /id="VAR_006217"
FT   VARIANT         14
FT                   /note="S -> F (in XLA; dbSNP:rs1057520682)"
FT                   /id="VAR_006218"
FT   VARIANT         19
FT                   /note="K -> E (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008291"
FT   VARIANT         25
FT                   /note="F -> S (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7711734"
FT                   /id="VAR_006219"
FT   VARIANT         27
FT                   /note="K -> R (in XLA)"
FT                   /id="VAR_008292"
FT   VARIANT         28
FT                   /note="R -> C (in XLA; no effect on phosphorylation of
FT                   GTF2I)"
FT                   /id="VAR_008293"
FT   VARIANT         28
FT                   /note="R -> H (in XLA; moderate; dbSNP:rs128620185)"
FT                   /evidence="ECO:0000269|PubMed:7849721,
FT                   ECO:0000269|PubMed:8162018, ECO:0000269|PubMed:9445504"
FT                   /id="VAR_006220"
FT   VARIANT         28
FT                   /note="R -> P (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8695804"
FT                   /id="VAR_006221"
FT   VARIANT         33
FT                   /note="T -> P (in XLA; severe; dbSNP:rs128620189)"
FT                   /evidence="ECO:0000269|PubMed:7633429,
FT                   ECO:0000269|PubMed:7849721"
FT                   /id="VAR_006222"
FT   VARIANT         39
FT                   /note="Y -> S (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:10612838"
FT                   /id="VAR_008960"
FT   VARIANT         40
FT                   /note="Y -> C (in XLA; dbSNP:rs1555980875)"
FT                   /id="VAR_008294"
FT   VARIANT         40
FT                   /note="Y -> N (in XLA)"
FT                   /id="VAR_008295"
FT   VARIANT         61
FT                   /note="I -> N (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008296"
FT   VARIANT         64
FT                   /note="V -> D (in XLA)"
FT                   /id="VAR_008297"
FT   VARIANT         64
FT                   /note="V -> F (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7849006"
FT                   /id="VAR_006223"
FT   VARIANT         82
FT                   /note="R -> K (in dbSNP:rs56035945)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041676"
FT   VARIANT         103
FT                   /note="Q -> QSVFSSTR (in XLA)"
FT                   /id="VAR_006224"
FT   VARIANT         113
FT                   /note="V -> D (in XLA; dbSNP:rs128621190)"
FT                   /evidence="ECO:0000269|PubMed:7849697"
FT                   /id="VAR_006225"
FT   VARIANT         115
FT                   /note="S -> F (in XLA)"
FT                   /id="VAR_008298"
FT   VARIANT         117
FT                   /note="T -> P (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008299"
FT   VARIANT         127
FT                   /note="Q -> H (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008300"
FT   VARIANT         154
FT                   /note="C -> S (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9280283"
FT                   /id="VAR_008301"
FT   VARIANT         155
FT                   /note="C -> G (in XLA)"
FT                   /id="VAR_008302"
FT   VARIANT         155
FT                   /note="C -> R (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9280283,
FT                   ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008303"
FT   VARIANT         184
FT                   /note="T -> P (in XLA)"
FT                   /id="VAR_008304"
FT   VARIANT         190
FT                   /note="P -> K (in a lung large cell carcinoma sample;
FT                   somatic mutation; requires 2 nucleotide substitutions)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041677"
FT   VARIANT         260..280
FT                   /note="Missing (in XLA; severe)"
FT                   /evidence="ECO:0000269|PubMed:7849721"
FT                   /id="VAR_006226"
FT   VARIANT         288
FT                   /note="R -> Q (in XLA; dbSNP:rs1555978277)"
FT                   /evidence="ECO:0000269|PubMed:9545398"
FT                   /id="VAR_008305"
FT   VARIANT         288
FT                   /note="R -> W (in XLA; dbSNP:rs128621194)"
FT                   /evidence="ECO:0000269|PubMed:7711734,
FT                   ECO:0000269|PubMed:8162018, ECO:0000269|PubMed:8162056,
FT                   ECO:0000269|PubMed:8834236"
FT                   /id="VAR_006227"
FT   VARIANT         295
FT                   /note="L -> P (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8723128,
FT                   ECO:0000269|PubMed:9445504"
FT                   /id="VAR_006228"
FT   VARIANT         302
FT                   /note="G -> E (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7627183,
FT                   ECO:0000269|PubMed:8695804"
FT                   /id="VAR_006230"
FT   VARIANT         302
FT                   /note="G -> R (in XLA)"
FT                   /id="VAR_008306"
FT   VARIANT         302
FT                   /note="Missing (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7633429"
FT                   /id="VAR_006229"
FT   VARIANT         307
FT                   /note="R -> G (in XLA; loss of activity;
FT                   dbSNP:rs128621195)"
FT                   /evidence="ECO:0000269|PubMed:8162056"
FT                   /id="VAR_006231"
FT   VARIANT         307
FT                   /note="R -> T (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9545398"
FT                   /id="VAR_008307"
FT   VARIANT         308
FT                   /note="D -> E (in XLA)"
FT                   /id="VAR_008308"
FT   VARIANT         319
FT                   /note="V -> A (in XLA; moderate)"
FT                   /id="VAR_008309"
FT   VARIANT         334
FT                   /note="Y -> S (in XLA; dbSNP:rs128621196)"
FT                   /evidence="ECO:0000269|PubMed:7880320"
FT                   /id="VAR_006232"
FT   VARIANT         358
FT                   /note="L -> F (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7897635"
FT                   /id="VAR_006233"
FT   VARIANT         361
FT                   /note="Y -> C (in XLA; mild; dbSNP:rs28935478)"
FT                   /evidence="ECO:0000269|PubMed:7849697"
FT                   /id="VAR_006234"
FT   VARIANT         362
FT                   /note="H -> Q (in XLA)"
FT                   /id="VAR_006235"
FT   VARIANT         364
FT                   /note="H -> P (in XLA)"
FT                   /id="VAR_006236"
FT   VARIANT         365
FT                   /note="N -> Y (in XLA)"
FT                   /id="VAR_006237"
FT   VARIANT         366
FT                   /note="S -> F (in XLA)"
FT                   /id="VAR_008310"
FT   VARIANT         369
FT                   /note="L -> F (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008311"
FT   VARIANT         370
FT                   /note="I -> M (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7711734"
FT                   /id="VAR_006238"
FT   VARIANT         372
FT                   /note="R -> G (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008312"
FT   VARIANT         408
FT                   /note="L -> P (in XLA; moderate; dbSNP:rs128621198)"
FT                   /evidence="ECO:0000269|PubMed:7849721"
FT                   /id="VAR_006239"
FT   VARIANT         414
FT                   /note="G -> R (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008313"
FT   VARIANT         418
FT                   /note="Y -> H (in XLA; dbSNP:rs144079566)"
FT                   /id="VAR_006240"
FT   VARIANT         429
FT                   /note="I -> N (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8634718"
FT                   /id="VAR_006241"
FT   VARIANT         430
FT                   /note="K -> E (in XLA; loss of phosphorylation of GTF2I;
FT                   dbSNP:rs128620184)"
FT                   /evidence="ECO:0000269|PubMed:7809124"
FT                   /id="VAR_006242"
FT   VARIANT         430
FT                   /note="K -> R (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9545398"
FT                   /id="VAR_008314"
FT   VARIANT         445
FT                   /note="E -> D (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9545398"
FT                   /id="VAR_008315"
FT   VARIANT         462
FT                   /note="G -> D (in XLA)"
FT                   /id="VAR_008316"
FT   VARIANT         462
FT                   /note="G -> V (in XLA)"
FT                   /id="VAR_008317"
FT   VARIANT         476
FT                   /note="Y -> D (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7627183"
FT                   /id="VAR_006243"
FT   VARIANT         477
FT                   /note="M -> R (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8634718"
FT                   /id="VAR_006244"
FT   VARIANT         481
FT                   /note="C -> S (found in patients with chronic lymphocytic
FT                   leukemia; unknown pathological significance; results in
FT                   resistance to ibrutinib therapy; results in a protein that
FT                   is reversibly inhibited by ibrutinib; disrupts the covalent
FT                   binding between the enzyme and ibrutinib;
FT                   dbSNP:rs1057519825 and dbSNP:rs1057519826)"
FT                   /evidence="ECO:0000269|PubMed:24869597,
FT                   ECO:0000269|PubMed:24869598, ECO:0000269|PubMed:25189416"
FT                   /id="VAR_074309"
FT   VARIANT         502
FT                   /note="C -> F (in XLA)"
FT                   /id="VAR_006245"
FT   VARIANT         502
FT                   /note="C -> W (in XLA; dbSNP:rs41310709)"
FT                   /evidence="ECO:0000269|PubMed:8695804"
FT                   /id="VAR_006246"
FT   VARIANT         506
FT                   /note="C -> R (in XLA; dbSNP:rs128621200)"
FT                   /evidence="ECO:0000269|PubMed:7880320"
FT                   /id="VAR_006247"
FT   VARIANT         506
FT                   /note="C -> Y (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_006248"
FT   VARIANT         508
FT                   /note="A -> D (in XLA)"
FT                   /id="VAR_008318"
FT   VARIANT         509
FT                   /note="M -> I (in XLA)"
FT                   /id="VAR_008319"
FT   VARIANT         509
FT                   /note="M -> V (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7711734"
FT                   /id="VAR_006249"
FT   VARIANT         512
FT                   /note="L -> P (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:10612838"
FT                   /id="VAR_008961"
FT   VARIANT         512
FT                   /note="L -> Q (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:10612838"
FT                   /id="VAR_008962"
FT   VARIANT         518
FT                   /note="L -> R (in XLA)"
FT                   /id="VAR_008320"
FT   VARIANT         520
FT                   /note="R -> Q (in XLA; severe; prevents activation due to
FT                   absence of contact between the catalytic loop and the
FT                   regulatory phosphorylated residue; dbSNP:rs128621202)"
FT                   /evidence="ECO:0000269|PubMed:7633429,
FT                   ECO:0000269|PubMed:7809124, ECO:0000269|PubMed:7849697,
FT                   ECO:0000269|PubMed:7880320"
FT                   /id="VAR_006251"
FT   VARIANT         521
FT                   /note="D -> G (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008321"
FT   VARIANT         521
FT                   /note="D -> H (in XLA; severe)"
FT                   /evidence="ECO:0000269|PubMed:8695804"
FT                   /id="VAR_006252"
FT   VARIANT         521
FT                   /note="D -> N (in XLA; severe)"
FT                   /id="VAR_006253"
FT   VARIANT         523
FT                   /note="A -> E (in XLA)"
FT                   /id="VAR_008322"
FT   VARIANT         525
FT                   /note="R -> G (in XLA; dbSNP:rs886041149)"
FT                   /evidence="ECO:0000269|PubMed:9545398"
FT                   /id="VAR_008323"
FT   VARIANT         525
FT                   /note="R -> P (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7711734"
FT                   /id="VAR_006254"
FT   VARIANT         525
FT                   /note="R -> Q (in XLA; severe; disturbs ATP-binding;
FT                   dbSNP:rs128620183)"
FT                   /evidence="ECO:0000269|PubMed:7809124,
FT                   ECO:0000269|PubMed:9445504"
FT                   /id="VAR_006255"
FT   VARIANT         526
FT                   /note="N -> K (in XLA; dbSNP:rs1569291237)"
FT                   /evidence="ECO:0000269|PubMed:7711734"
FT                   /id="VAR_006256"
FT   VARIANT         535
FT                   /note="V -> F (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9545398"
FT                   /id="VAR_008324"
FT   VARIANT         542
FT                   /note="L -> P (in XLA; growth hormone deficiency;
FT                   dbSNP:rs128621203)"
FT                   /evidence="ECO:0000269|PubMed:7849697"
FT                   /id="VAR_006257"
FT   VARIANT         544
FT                   /note="R -> G (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:10612838"
FT                   /id="VAR_008963"
FT   VARIANT         544
FT                   /note="R -> K (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8834236"
FT                   /id="VAR_006258"
FT   VARIANT         559
FT                   /note="F -> S (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008325"
FT   VARIANT         562
FT                   /note="R -> P (in XLA; dbSNP:rs104894770)"
FT                   /evidence="ECO:0000269|PubMed:10678660,
FT                   ECO:0000269|PubMed:7809124"
FT                   /id="VAR_006259"
FT   VARIANT         562
FT                   /note="R -> W (in XLA; dbSNP:rs128621204)"
FT                   /evidence="ECO:0000269|PubMed:7711734,
FT                   ECO:0000269|PubMed:7849697, ECO:0000269|PubMed:7880320,
FT                   ECO:0000269|PubMed:9445504"
FT                   /id="VAR_006260"
FT   VARIANT         563
FT                   /note="W -> L (in XLA; dbSNP:rs1555977474)"
FT                   /evidence="ECO:0000269|PubMed:9545398"
FT                   /id="VAR_008326"
FT   VARIANT         567
FT                   /note="E -> K (in XLA; severe)"
FT                   /evidence="ECO:0000269|PubMed:7633420"
FT                   /id="VAR_006261"
FT   VARIANT         578
FT                   /note="S -> Y (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:10612838"
FT                   /id="VAR_008964"
FT   VARIANT         581
FT                   /note="W -> R (in XLA; dbSNP:rs128621205)"
FT                   /id="VAR_006262"
FT   VARIANT         582
FT                   /note="A -> V (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7711734,
FT                   ECO:0000269|PubMed:7809124"
FT                   /id="VAR_006263"
FT   VARIANT         583
FT                   /note="F -> S (in XLA)"
FT                   /id="VAR_008327"
FT   VARIANT         587
FT                   /note="M -> L (in XLA; mild; dbSNP:rs1603001822)"
FT                   /evidence="ECO:0000269|PubMed:7633420"
FT                   /id="VAR_006264"
FT   VARIANT         589
FT                   /note="E -> D (in XLA)"
FT                   /id="VAR_008328"
FT   VARIANT         589
FT                   /note="E -> G (in XLA; moderate; interferes with substrate
FT                   binding; dbSNP:rs128621206)"
FT                   /evidence="ECO:0000269|PubMed:7809124,
FT                   ECO:0000269|PubMed:7849721"
FT                   /id="VAR_006265"
FT   VARIANT         589
FT                   /note="E -> K (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:10612838"
FT                   /id="VAR_008965"
FT   VARIANT         592
FT                   /note="S -> P (in XLA; dbSNP:rs1603001783)"
FT                   /evidence="ECO:0000269|PubMed:8834236"
FT                   /id="VAR_006267"
FT   VARIANT         594
FT                   /note="G -> E (in XLA; mild; interferes with substrate
FT                   binding)"
FT                   /evidence="ECO:0000269|PubMed:7809124,
FT                   ECO:0000269|PubMed:9445504"
FT                   /id="VAR_006268"
FT   VARIANT         594
FT                   /note="G -> R (in XLA; dbSNP:rs1555977339)"
FT                   /evidence="ECO:0000269|PubMed:7711734"
FT                   /id="VAR_006269"
FT   VARIANT         598
FT                   /note="Y -> C (in XLA)"
FT                   /id="VAR_006270"
FT   VARIANT         607
FT                   /note="A -> D (in XLA; mild; dbSNP:rs128621208)"
FT                   /evidence="ECO:0000269|PubMed:8162056"
FT                   /id="VAR_006271"
FT   VARIANT         613
FT                   /note="G -> D (in XLA; mild; interferes with substrate
FT                   binding and/or domain interactions; dbSNP:rs128621209)"
FT                   /evidence="ECO:0000269|PubMed:7809124,
FT                   ECO:0000269|PubMed:7849721"
FT                   /id="VAR_006272"
FT   VARIANT         619
FT                   /note="P -> A (in XLA)"
FT                   /id="VAR_008330"
FT   VARIANT         619
FT                   /note="P -> S (in XLA)"
FT                   /id="VAR_006273"
FT   VARIANT         619
FT                   /note="P -> T (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008331"
FT   VARIANT         622
FT                   /note="A -> P (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9545398"
FT                   /id="VAR_008332"
FT   VARIANT         626
FT                   /note="V -> G (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:9445504"
FT                   /id="VAR_008333"
FT   VARIANT         630
FT                   /note="M -> I"
FT                   /id="VAR_006274"
FT   VARIANT         630
FT                   /note="M -> K (in XLA; dbSNP:rs128621210)"
FT                   /evidence="ECO:0000269|PubMed:7849697,
FT                   ECO:0000269|PubMed:7880320"
FT                   /id="VAR_006275"
FT   VARIANT         630
FT                   /note="M -> T (in XLA)"
FT                   /id="VAR_008334"
FT   VARIANT         633
FT                   /note="C -> Y (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8695804"
FT                   /id="VAR_006276"
FT   VARIANT         641
FT                   /note="R -> C (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:7633429"
FT                   /id="VAR_006277"
FT   VARIANT         641
FT                   /note="R -> H (in XLA; severe)"
FT                   /evidence="ECO:0000269|PubMed:7633420,
FT                   ECO:0000269|PubMed:9445504"
FT                   /id="VAR_006278"
FT   VARIANT         644
FT                   /note="F -> L (in XLA)"
FT                   /id="VAR_008335"
FT   VARIANT         644
FT                   /note="F -> S (in XLA)"
FT                   /evidence="ECO:0000269|PubMed:8695804"
FT                   /id="VAR_006279"
FT   VARIANT         647
FT                   /note="L -> P (in XLA)"
FT                   /id="VAR_006280"
FT   VARIANT         652
FT                   /note="L -> P (in XLA; dbSNP:rs128622212)"
FT                   /evidence="ECO:0000269|PubMed:7849697"
FT                   /id="VAR_006281"
FT   MUTAGEN         41
FT                   /note="E->K: No effect on phosphorylation of GTF2I."
FT                   /evidence="ECO:0000269|PubMed:9012831"
FT   MUTAGEN         189
FT                   /note="P->A: No effect on phosphorylation of GTF2I."
FT                   /evidence="ECO:0000269|PubMed:9012831"
FT   MUTAGEN         223
FT                   /note="Y->F: Loss of phosphorylation of GTF2I."
FT                   /evidence="ECO:0000269|PubMed:8630736,
FT                   ECO:0000269|PubMed:9012831"
FT   MUTAGEN         251..252
FT                   /note="WW->LL: Large decrease in binding by SH3BP5."
FT                   /evidence="ECO:0000269|PubMed:9571151"
FT   MUTAGEN         251
FT                   /note="W->L: No effect on phosphorylation of GTF2I."
FT                   /evidence="ECO:0000269|PubMed:9012831"
FT   MUTAGEN         307
FT                   /note="R->K: Loss of phosphorylation of GTF2I."
FT                   /evidence="ECO:0000269|PubMed:9012831"
FT   MUTAGEN         551
FT                   /note="Y->F: Loss of phosphorylation of GTF2I."
FT                   /evidence="ECO:0000269|PubMed:9012831"
FT   MUTAGEN         617
FT                   /note="Y->E: Defective in mediating calcium response."
FT                   /evidence="ECO:0000269|PubMed:15375214"
FT   CONFLICT        253
FT                   /note="R -> K (in Ref. 7; BAG37008)"
FT                   /evidence="ECO:0000305"
FT   STRAND          5..13
FT                   /evidence="ECO:0007829|PDB:6TT2"
FT   STRAND          15..17
FT                   /evidence="ECO:0007829|PDB:6TUH"
FT   STRAND          19..21
FT                   /evidence="ECO:0007829|PDB:6TUH"
FT   STRAND          25..32
FT                   /evidence="ECO:0007829|PDB:6TT2"
FT   STRAND          34..43
FT                   /evidence="ECO:0007829|PDB:6TT2"
FT   TURN            44..47
FT                   /evidence="ECO:0007829|PDB:6TT2"
FT   STRAND          48..57
FT                   /evidence="ECO:0007829|PDB:6TT2"
FT   HELIX           58..60
FT                   /evidence="ECO:0007829|PDB:6TT2"
FT   STRAND          63..66
FT                   /evidence="ECO:0007829|PDB:6TT2"
FT   HELIX           75..77
FT                   /evidence="ECO:0007829|PDB:6TT2"
FT   STRAND          82..85
FT                   /evidence="ECO:0007829|PDB:6YYG"
FT   HELIX           93..96
FT                   /evidence="ECO:0007829|PDB:6TT2"
FT   STRAND          100..106
FT                   /evidence="ECO:0007829|PDB:6TT2"
FT   STRAND          109..117
FT                   /evidence="ECO:0007829|PDB:6TT2"
FT   HELIX           118..132
FT                   /evidence="ECO:0007829|PDB:6TT2"
FT   STRAND          140..142
FT                   /evidence="ECO:0007829|PDB:6TT2"
FT   STRAND          149..152
FT                   /evidence="ECO:0007829|PDB:2Z0P"
FT   TURN            153..155
FT                   /evidence="ECO:0007829|PDB:6TT2"
FT   STRAND          165..167
FT                   /evidence="ECO:0007829|PDB:6TT2"
FT   TURN            212..215
FT                   /evidence="ECO:0007829|PDB:1AWX"
FT   STRAND          218..223
FT                   /evidence="ECO:0007829|PDB:1AWW"
FT   STRAND          228..232
FT                   /evidence="ECO:0007829|PDB:1AWW"
FT   STRAND          240..242
FT                   /evidence="ECO:0007829|PDB:1AWW"
FT   STRAND          248..252
FT                   /evidence="ECO:0007829|PDB:1AWW"
FT   TURN            257..259
FT                   /evidence="ECO:0007829|PDB:1QLY"
FT   STRAND          261..265
FT                   /evidence="ECO:0007829|PDB:1AWX"
FT   TURN            266..268
FT                   /evidence="ECO:0007829|PDB:1AWW"
FT   STRAND          279..282
FT                   /evidence="ECO:0007829|PDB:2GE9"
FT   HELIX           288..298
FT                   /evidence="ECO:0007829|PDB:6HTF"
FT   STRAND          303..308
FT                   /evidence="ECO:0007829|PDB:6HTF"
FT   STRAND          310..313
FT                   /evidence="ECO:0007829|PDB:6HTF"
FT   STRAND          315..321
FT                   /evidence="ECO:0007829|PDB:6HTF"
FT   STRAND          330..335
FT                   /evidence="ECO:0007829|PDB:6HTF"
FT   STRAND          337..339
FT                   /evidence="ECO:0007829|PDB:2GE9"
FT   TURN            340..342
FT                   /evidence="ECO:0007829|PDB:2GE9"
FT   STRAND          344..347
FT                   /evidence="ECO:0007829|PDB:6HTF"
FT   STRAND          352..354
FT                   /evidence="ECO:0007829|PDB:6HTF"
FT   HELIX           355..362
FT                   /evidence="ECO:0007829|PDB:6HTF"
FT   STRAND          369..371
FT                   /evidence="ECO:0007829|PDB:6HTF"
FT   STRAND          373..376
FT                   /evidence="ECO:0007829|PDB:2GE9"
FT   HELIX           393..395
FT                   /evidence="ECO:0007829|PDB:6O8I"
FT   HELIX           399..401
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   STRAND          402..410
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   STRAND          412..414
FT                   /evidence="ECO:0007829|PDB:6W7O"
FT   STRAND          415..421
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   TURN            422..424
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   STRAND          425..431
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   TURN            434..436
FT                   /evidence="ECO:0007829|PDB:5FBO"
FT   HELIX           439..450
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   STRAND          460..464
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   STRAND          466..469
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   STRAND          471..474
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   HELIX           482..487
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   HELIX           489..491
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   HELIX           495..514
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   TURN            524..526
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   STRAND          527..529
FT                   /evidence="ECO:0007829|PDB:6DI1"
FT   STRAND          535..537
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   HELIX           542..545
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   HELIX           549..551
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   STRAND          556..559
FT                   /evidence="ECO:0007829|PDB:6NFH"
FT   HELIX           561..563
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   HELIX           566..571
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   HELIX           576..591
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   TURN            592..594
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   TURN            597..600
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   HELIX           603..611
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   HELIX           624..632
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   HELIX           638..640
FT                   /evidence="ECO:0007829|PDB:5P9J"
FT   HELIX           644..657
FT                   /evidence="ECO:0007829|PDB:5P9J"
SQ   SEQUENCE   659 AA;  76281 MW;  DF06B5D1FEC257CC CRC64;
     MAAVILESIF LKRSQQKKKT SPLNFKKRLF LLTVHKLSYY EYDFERGRRG SKKGSIDVEK
     ITCVETVVPE KNPPPERQIP RRGEESSEME QISIIERFPY PFQVVYDEGP LYVFSPTEEL
     RKRWIHQLKN VIRYNSDLVQ KYHPCFWIDG QYLCCSQTAK NAMGCQILEN RNGSLKPGSS
     HRKTKKPLPP TPEEDQILKK PLPPEPAAAP VSTSELKKVV ALYDYMPMNA NDLQLRKGDE
     YFILEESNLP WWRARDKNGQ EGYIPSNYVT EAEDSIEMYE WYSKHMTRSQ AEQLLKQEGK
     EGGFIVRDSS KAGKYTVSVF AKSTGDPQGV IRHYVVCSTP QSQYYLAEKH LFSTIPELIN
     YHQHNSAGLI SRLKYPVSQQ NKNAPSTAGL GYGSWEIDPK DLTFLKELGT GQFGVVKYGK
     WRGQYDVAIK MIKEGSMSED EFIEEAKVMM NLSHEKLVQL YGVCTKQRPI FIITEYMANG
     CLLNYLREMR HRFQTQQLLE MCKDVCEAME YLESKQFLHR DLAARNCLVN DQGVVKVSDF
     GLSRYVLDDE YTSSVGSKFP VRWSPPEVLM YSKFSSKSDI WAFGVLMWEI YSLGKMPYER
     FTNSETAEHI AQGLRLYRPH LASEKVYTIM YSCWHEKADE RPTFKILLSN ILDVMDEES
//
